Key result
Magmaris bioresorbable stenting in a 1,980 g infant with aortic coarctation resulted in significant early stent restenosis and complete loss of radial force requiring reangioplasty at 21 days.
Why the study?
Does Magmaris bioresorbable stenting provide a safe and effective bridge to surgery in a low birth weight infant with native aortic coarctation?
Case Report (n=1)
Does Magmaris bioresorbable stenting provide a safe and effective bridge to surgery in a low birth weight infant with native aortic coarctation?
Magmaris bioresorbable stenting in a low birth weight infant with aortic coarctation resulted in early stent failure and high systemic sirolimus levels, suggesting it is not promising for long-term bridging in this population.
Answers are grounded in this paper and cite their sources.
Caution advised against Magmaris for bridging in low birth weight coarctation; leaves open bioresorbable stent role in neonates.
We, herein, report the first use of a Magmaris® magnesium-based vascular scaffold for native aortic coarctation in a 1,980 g infant with multiple malformations. Due to the low body weight, complex illness, and clinical instability, it was decided to delay surgical correction. After insufficient results had been obtained by balloon angioplasty, Magmaris® implantation was chosen to bridge the patient to surgery by stabilizing left ventricular function and to allow for sufficient growth. Due to significant early stent restenosis and complete loss of radial force, the patient required balloon reangioplasty only 21 days after Magmaris® implantation and early surgical correction. In addition, high systemic sirolimus levels were detected 48 hr after the intervention (5 ng/mL). Although the bioresorbable scaffold was successfully used as a short-term bridge-to-surgery in our case, due to significant early stent failure (loss of radial force), this approach does not seem promising for long-term bridging of infants with aortic coarctation. In addition, the consequences of sirolimus-induced systemic immunosuppression may further limit the applicability of Magmaris® scaffolds in infants with congenital heart disease.
No takes yet. Share an insight, caveat, or question.
Sallmon et al. (2019) conducted a case report in Native aortic coarctation (n=1). Magmaris magnesium-based vascular scaffold was evaluated on Clinical outcome (stent restenosis and loss of radial force). Magmaris bioresorbable stenting in a 1,980 g infant with aortic coarctation resulted in significant early stent restenosis and complete loss of radial force requiring reangioplasty at 21 days.
Synapse has enriched 10 related papers. Consider them for comparative context: